Compare Medpace Holdings Inc (MEDP) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Meta Platforms Inc — how do they compare? Medpace Holdings Inc trades at $617.76 (market cap $16.82B), while Meta Platforms Inc trades at $720.57 (market cap $1.84T). The key difference: Meta Platforms Inc is far larger — about 109.4× Medpace Holdings Inc's market cap, and Meta Platforms Inc pays a 0.29% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Meta Platforms Inc for 127 Days on average.
| MEDP | META | |
|---|---|---|
Market Cap | $16.82B | $1.84T |
Volume | 223,093 | 15,887,049 |
Sector | Health | Media |
52-Week High | $630.19 | $777.59 |
52-Week Low | $393.42 | $525.72 |
Typical Hold Time | 14 Days | 127 Days |
Enterprise Value | $16.44B | $1.86T |
Dividend Yield | — | 0.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
META trades at $723.54, up 0.31% on the day, with a bullish technical signal from moving averages and support at $714. The company reported strong revenue growth to $201.0B in 2025 and a net income margin of 29.84%, though Q2 2026 EPS missed expectations. Recent news highlights the launch of its Muse Spark AI model and a $21B deal with CoreWeave, driving positive sentiment.
The outlook is positive with an 80% analyst buy rating and a consensus price target of $781, but risks include ongoing youth addiction lawsuits and high capital expenditures. Revenue is projected to grow to $228.2B in 2026, supporting long-term growth despite near-term legal and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
